Cardlytics, Inc. - Common Stock (CDLX)

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cardlytics To Contact Him Directly To Discuss Their Options

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQCDLX) in the United States District Court for the Northern District of Georgia on behalf of all persons and entities who purchased or otherwise acquired Cardlytics securities between March 14, 2024 and August 7, 2024, both dates inclusive (the “Class Period”). Investors have until March 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cardlytics, Inc. (“Cardlytics” or “the Company”) (NASDAQCDLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Cardlytics, Inc. (NASDAQCDLX) between March 14, 2024 and August 7, 2024. Cardlytics describes itself as a company that “operates an advertising platform in the United States and the United Kingdom.”

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQCDLX) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) --

Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of Georgia, captioned Froess v. Cardlytics, Inc., et al., Case No. 1:25-cv-279, on behalf of persons and entities that purchased or otherwise acquired Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQCDLX) securities between March 14, 2024 and August 7, 2024, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQCDLX) investors concerning the Company’s possible violations of the federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQCDLX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQCDLX) investors concerning the Company’s possible violations of federal securities laws.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. (“Cardlytics” or “the Company”) (NASDAQCDLX) for violations of the securities laws.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cardlytics, Inc. (NASDAQCDLX) resulting from allegations that Cardlytics may have issued materially misleading business information to the investing public.

ATLANTA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQCDLX), a digital advertising platform, today announced financial results for the third quarter ended September 30, 2024.

SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company’s Board of Directors (the “Board”), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board’s Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In addition, Mr. Jensen has been appointed to serve as the Board’s Lead Independent Director.

ATLANTA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQCDLX), an advertising platform in banks’ digital channels, today announced that its financial results for the third quarter ending September 30, 2024 will be released on November 6, 2024, after market close. The results will be discussed via conference call at 5:00 PM ET / 2:00 PM PT.

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cardlytics, Inc. (NASDAQCDLX), Medpace Holdings, Inc. NASDAQ: MEDPNASDAQMEDP)(NYSE: CUBINYSECUBI, and Ibotta, Inc. (NYSE:IBTANYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against LPL Financial Holdings Inc. (NASDAQLPLA), Bumble Inc. NASDAQ:BMBLNASDAQBMBL)(NASDAQ: CDLXNASDAQCDLX, and European Wax Center, Inc. (NASDAQ:EWCZNASDAQ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Paragon 28, Inc. (NYSEFNA), Bumble Inc. NASDAQ:BMBLNASDAQBMBL)(NASDAQ: CDLXNASDAQCDLX, and NuScale Power Corp. (NYSE:SMRNYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Arhaus, Inc (NASDAQARHS), Cardlytics, Inc. NASDAQ: CDLXNASDAQCDLX)(NASDAQ: CVRXNASDAQCVRX. Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cardlytics, Inc. (“Cardlytics” or “the Company”) (NASDAQCDLX). Investors who purchased Cardlytics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CDLX.

ATLANTA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQCDLX), an advertising platform in banks’ digital channels, today announced that, on August 19, 2024, the Compensation Committee of Cardlytics’ Board of Directors granted an aggregate of 49,900 restricted stock units of Cardlytics to seven newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the “2022 Inducement Plan”).

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cardlytics, Inc. (“Cardlytics” or “the Company”) (NASDAQCDLX). Investors who purchased Cardlytics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CDLX.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - (NewMediaWire) - August 15, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cardlytics, Inc. (CDLX) (“Cardlytics” or the “Company”) (NASDAQCDLX).

 NEW YORK, NY - (NewMediaWire) - August 14, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cardlytics, Inc. (CDLX) (“Cardlytics” or the “Company”) (NASDAQCDLX).